PDCD1 and renal cell carcinoma: In contrast, other studies find that overweight or obese RCC patients had longer PFS, better overall survival outcomes, and lower time-to-treatment failure after receiving anti-PD-1/PD-L1 treatments compared to control non-obese groups [78].